RAS isoforms and mutations in cancer at a glance

Journal of Cell Science

Volumn 129, Issue 7, 2016, Pages 1287-1292

  Hobbs, G Aaron ^a   Der, Channing J ^a   Rossman, Kent L ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

GTPase; Oncogene; PI3K; Rac; Raf; Ral

Indexed keywords

H RAS PROTEIN; K RAS PROTEIN; N RAS PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG; ISOPROTEIN; PROTEIN P21; STOP CODON;

ARTICLE; GENE MUTATION; GENE STRUCTURE; GENETIC VARIATION; HUMAN; MISSENSE MUTATION; NEOPLASM; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; PRIORITY JOURNAL; GENETICS; STOP CODON;

CODON, NONSENSE; HUMANS; MUTATION, MISSENSE; NEOPLASMS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 84964345721     PISSN: 00219533     EISSN: 14779137     Source Type: Journal    
DOI: 10.1242/jcs.182873     Document Type: Article

References (76)

1. Abankwa, D., Gorfe, A. A. and Hancock, J. F. (2008). Mechanisms of Ras membrane organization and signaling: Ras on a rocker. Cell Cycle 7, 2667-2673.
2. Abankwa, D., Gorfe, A. A., Inder, K. and Hancock, J. F. (2010). Ras membrane orientation and nanodomain localization generate isoform diversity. Proc. Natl. Acad. Sci. USA 107, 1130-1135.
3. Ahearn, I. M., Haigis, K., Bar-Sagi, D. and Philips, M. R. (2012). Regulating the regulator: post-translational modification of RAS. Nat. Rev. Mol. Cell Biol. 13, 39-51.
4. Allegra, C. J., Jessup, J. M., Somerfield, M. R., Hamilton, S. R., Hammond, E. H., Hayes, D. F., McAllister, P. K., Morton, R. F. and Schilsky, R. L. (2009). American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27, 2091-2096.
5. Baker, R., Lewis, S. M., Sasaki, A. T., Wilkerson, E. M., Locasale, J.W., Cantley, L. C., Kuhlman, B., Dohlman, H. G. and Campbell, S. L. (2013a). Site-specific monoubiquitination activates Ras by impeding GTPase-activating protein function. Nat. Struct. Mol. Biol. 20, 46-52.
6. Baker, R., Wilkerson, E. M., Sumita, K., Isom, D. G., Sasaki, A. T., Dohlman, H. G. and Campbell, S. L. (2013b). Differences in the regulation of K-Ras and H-Ras isoforms by monoubiquitination. J. Biol. Chem. 288, 36856-36862.
7. Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C. et al. (2009). Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108-112.
8. Barcelo, C., Paco, N., Morell, M., Alvarez-Moya, B., Bota-Rabassedas, N., Jaumot, M., Vilardell, F., Capella, G. and Agell, N. (2014). Phosphorylation at Ser-181 of oncogenic KRAS is required for tumor growth. Cancer Res. 74, 1190-1199.
9. Bremner, R. and Balmain, A. (1990). Genetic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7. Cell 61, 407-417.
10. Bryant, K. L., Mancias, J. D., Kimmelman, A. C. and Der, C. J. (2014). KRAS: feeding pancreatic cancer proliferation. Trends Biochem. Sci. 39, 91-100.
11. Buhrman, G., Wink, G. and Mattos, C. (2007). Transformation efficiency of RasQ61 mutants linked to structural features of the switch regions in the presence of Raf. Structure 15, 1618-1629.
12. Buhrman, G., O'Connor, C., Zerbe, B., Kearney, B. M., Napoleon, R., Kovrigina, E. A., Vajda, S., Kozakov, D., Kovrigin, E. L. and Mattos, C. (2011). Analysis of binding site hot spots on the surface of Ras GTPase. J. Mol. Biol. 413, 773-789.
13. Bunda, S., Heir, P., Srikumar, T., Cook, J. D., Burrell, K., Kano, Y., Lee, J. E., Zadeh, G., Raught, B. and Ohh, M. (2014). Src promotes GTPase activity of Ras via tyrosine 32 phosphorylation. Proc. Natl. Acad. Sci. USA 111, E3785-E3794.
14. Burd, C. E., Liu, W., Huynh, M. V., Waqas, M. A., Gillahan, J. E., Clark, K. S., Fu, K., Martin, B. L., Jeck, W. R., Souroullas, G. P. et al. (2014). Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. Cancer Discov. 4, 1418-1429.
15. Cox, A. D. and Der, C. J. (2010). Ras history: the saga continues. Small GTPases 1, 2-27.
16. Cox, A. D., Fesik, S.W., Kimmelman, A. C., Luo, J. and Der, C. J. (2014). Drugging the undruggable RAS: mission possible? Nat. Rev. Drug Discov. 13, 828-851.
17. Cox, A. D., Der, C.J. and Philips, M. R. (2015). Targeting RAS membrane association: back to the future for anti-RAS drug discovery? Clin. Cancer Res. 21, 1819-1827.
18. Der, C. J., Finkel, T. and Cooper, G. M. (1986). Biological and biochemical properties of human rasH genes mutated at codon 61. Cell 44, 167-176.
19. Eisenberg, S., Beckett, A. J., Prior, I. A., Dekker, F. J., Hedberg, C., Waldmann, H., Ehrlich, M. and Henis, Y. I. (2011). Raft protein clustering alters N-Ras membrane interactions and activation pattern. Mol. Cell. Biol. 31, 3938-3952.
20. Faris, J. E., Borger, D. R., Fernandez-del Castillo, C., Clark, J.W., Blaszkowsky, L. S., Zhu, A. X., Allen, J. N., Murphy, J. E., Ferrone, C., Goyal, L. et al. (2014). Effect of molecular genotyping to predict outcomes in patients with metastatic pancreatic cancer. J. Clin. Oncol. 32, 5s; abstract 4128.
21. Fetics, S. K., Guterres, H., Kearney, B. M., Buhrman, G., Ma, B., Nussinov, R. and Mattos, C. (2015). Allosteric effects of the oncogenic RasQ61L mutant on Raf-RBD. Structure 23, 505-516.
22. Fruman, D. A. and Rommel, C. (2014). PI3K and cancer: lessons, challenges and opportunities. Nat. Rev. Drug Discov. 13, 140-156.
23. Gelabert-Baldrich, M., Soriano-Castell, D., Calvo, M., Lu, A., Vina-Vilaseca, A., Rentero, C., Pol, A., Grinstein, S., Enrich, C. and Tebar, F. (2014). Dynamics of KRas on endosomes: involvement of acidic phospholipids in its association. FASEB J. 28, 3023-3037.
24. Grabocka, E., Pylayeva-Gupta, Y., Jones, M. J. K., Lubkov, V., Yemanaberhan, E., Taylor, L., Jeng, H. H. and Bar-Sagi, D. (2014). Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response. Cancer Cell 25, 243-256.
25. Haigis, K. M., Kendall, K. R., Wang, Y., Cheung, A., Haigis, M. C., Glickman, J. N., Niwa-Kawakita, M., Sweet-Cordero, A., Sebolt-Leopold, J., Shannon, K. M. et al. (2008). Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat. Genet. 40, 600-608.
26. Hammond, D. E., Mageean, C. J., Rusilowicz, E.V., Wickenden, J. A., Clague, M. J. and Prior, I.A. (2015). Differential reprogramming of isogenic colorectal cancercells by distinct activating KRAS mutations. J. Proteome Res. 14, 1535-1546.
27. Hunter, J. C., Gurbani, D., Ficarro, S. B., Carrasco, M. A., Lim, S. M., Choi, H. G., Xie, T., Marto, J. A., Chen, Z., Gray, N. S. et al. (2014). In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C. Proc. Natl. Acad. Sci. USA 111, 8895-8900.
28. Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S. and Westover, K. D. (2015). Biochemical and structural analysis of common cancerassociated KRAS mutations. Mol. Cancer Res. 13, 1325-1335.
29. Ihle, N. T., Byers, L. A., Kim, E. S., Saintigny, P., Lee, J. J., Blumenschein, G. R., Tsao, A., Liu, S., Larsen, J. E., Wang, J. et al. (2012). Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J. Natl. Cancer Inst. 104, 228-239.
30. Jang, H., Abraham, S. J., Chavan, T. S., Hitchinson, B., Khavrutskii, L., Tarasova, N. I., Nussinov, R. and Gaponenko, V. (2015). Mechanisms of membrane binding of small GTPase K-Ras4B farnesylated hypervariable region. J. Biol. Chem. 290, 9465-9477.
31. Jura, N., Scotto-Lavino, E., Sobczyk, A. and Bar-Sagi, D. (2006). Differential modification of Ras proteins by ubiquitination. Mol. Cell 21, 679-687.
32. Khrenova, M. G., Mironov, V. A., Grigorenko, B. L. and Nemukhin, A. V. (2014). Modeling the role of G12V and G13V Ras mutations in the Ras-GAP-catalyzed hydrolysis reaction of guanosine triphosphate. Biochemistry 53, 7093-7099.
33. Kiel, C., Wohlgemuth, S., Rousseau, F., Schymkowitz, J., Ferkinghoff-Borg, J., Wittinghofer, F. and Serrano, L. (2005). Recognizing and defining true Ras binding domains II: in silico prediction based on homology modelling and energy calculations. J. Mol. Biol. 348, 759-775.
34. Kumar, M. S., Hancock, D. C., Molina-Arcas, M., Steckel, M., East, P., Diefenbacher, M., Armenteros-Monterroso, E., Lassailly, F., Matthews, N., Nye, E. et al. (2012). The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149, 642-655.
35. Lampson, B. L., Pershing, N. L. K., Prinz, J. A., Lacsina, J. R., Marzluff, W. F., Nicchitta, C. V., MacAlpine, D. M. and Counter, C. M. (2013). Rare codons regulate KRas oncogenesis. Curr. Biol. 23, 70-75.
36. Ledford, H. (2015). Cancer: the Ras renaissance. Nature 520, 278-280.
37. Lim, K.-H., Ancrile, B. B., Kashatus, D. F. and Counter, C. M. (2008). Tumour maintenance is mediated by eNOS. Nature 452, 646-649.
38. Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K. and Elledge, S. J. (2009). Agenome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835-848.
39. Lynch, S. J., Snitkin, H., Gumper, I., Philips, M. R., Sabatini, D. and Pellicer, A. (2015). The differential palmitoylation states of N-Ras and H-Ras determine their distinct golgi subcompartment localizations. J. Cell. Physiol. 230, 610-619.
40. Maurer, T., Garrenton, L. S., Oh, A., Pitts, K., Anderson, D. J., Skelton, N. J., Fauber, B. P., Pan, B., Malek, S., Stokoe, D. et al. (2012). Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc. Natl. Acad. Sci. USA 109, 5299-5304.
41. Ogura, T., Yamao, K., Hara, K., Mizuno, N., Hijioka, S., Imaoka, H., Sawaki, A., Niwa, Y., Tajika, M., Kondo, S. et al. (2013). Prognostic value of K-rasmutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer. J. Gastroenterol. 48, 640-646.
42. Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. and Shokat, K. M. (2013). K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548-551.
43. Parker, J. A. and Mattos, C. (2015). The Ras-membrane interface: isoform-specific differences in the catalytic domain. Mol. Cancer Res. 13, 595.
44. Pecot, C. V., Wu, S. Y., Bellister, S., Filant, J., Rupaimoole, R., Hisamatsu, T., Bhattacharya, R., Maharaj, A., Azam, S., Rodriguez-Aguayo, C. et al. (2014). Therapeutic silencing of KRAS using systemically delivered siRNAs. Mol. Cancer Ther. 13, 2876-2885.
45. Pershing, N. L. K., Lampson, B. L., Belsky, J. A., Kaltenbrun, E., MacAlpine, D. M. and Counter, C. M. (2015). Rare codons capacitate Kras-driven de novo tumorigenesis. J. Clin. Invest. 125, 222-233.
46. Prior, I. A., Lewis, P. D. and Mattos, C. (2012). A comprehensive survey of Ras mutations in cancer. Cancer Res. 72, 2457-2467.
47. Qiu, W., Sahin, F., Iacobuzio-Donahue, C. A., Garcia-Carracedo, D., Wang, W. M., Kuo, C.-Y., Chen, D., Arking, D. E., Lowy, A. M., Hruban, R. H. et al. (2011). Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo. Oncotarget 2, 862-873.
48. Quatela, S. E., Sung, P. J., Ahearn, I. M., Bivona, T. G. and Philips, M. R. (2008). Analysis of K-Ras phosphorylation, translocation, and induction of apoptosis. Small Gtpases Dis. Pt. B 439, 87-102.
49. Rotblat, B., Prior, I. A., Muncke, C., Parton, R. G., Kloog, Y., Henis, Y. I. and Hancock, J. F. (2004). Three separable domains regulate GTP-dependent association of H-ras with the plasma membrane. Mol. Cell. Biol. 24, 6799-6810.
50. Samatar, A. A. and Poulikakos, P. I. (2014). Targeting RAS-ERK signalling in cancer: promises and challenges. Nat. Rev. Drug Discov. 13, 928-942.
51. Sarthy, A. V., Morgan-Lappe, S. E., Zakula, D., Vernetti, L., Schurdak, M., Packer, J. C. L., Anderson, M. G., Shirasawa, S., Sasazuki, T. and Fesik, S.W. (2007). Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells. Mol. Cancer Ther. 6, 269-276.
52. Sasaki, A. T., Carracedo, A., Locasale, J. W., Anastasiou, D., Takeuchi, K., Kahoud, E. R., Haviv, S., Asara, J. M., Pandolfi, P. P. and Cantley, L. C. (2011). Ubiquitination of K-Ras enhances activation and facilitates binding to select downstream effectors. Sci. Signal. 4, ra13.
53. Scholl, C., Fröhling, S., Dunn, I. F., Schinzel, A. C., Barbie, D. A., Kim, S. Y., Silver, S. J., Tamayo, P., Wadlow, R. C., Ramaswamy, S. et al. (2009). Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137, 821-834.
54. Seeburg, P. H., Colby, W. W., Capon, D. J., Goeddel, D. V. and Levinson, A. D. (1984). Biological properties of human c-Ha-ras1 genes mutated at codon 12. Nature 312, 71-75.
55. Shima, F., Yoshikawa, Y., Ye, M., Araki, M., Matsumoto, S., Liao, J., Hu, L., Sugimoto, T., Ijiri, Y., Takeda, A. et al. (2013). In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction. Proc. Natl. Acad. Sci. USA 110, 8182-8187.
56. Smith, M. J., Neel, B. G. and Ikura, M. (2013). NMR-based functional profiling of RASopathies and oncogenic RAS mutations. Proc. Natl. Acad. Sci. USA 110, 4574-4579.
57. Sun, Q., Burke, J. P., Phan, J., Burns, M. C., Olejniczak, E. T., Waterson, A. G., Lee, T., Rossanese, O.W. and Fesik, S.W. (2012). Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew. Chem. Int. Ed. Engl. 51, 6140-6143.
58. Tejpar, S., Celik, I., Schlichting, M., Sartorius, U., Bokemeyer, C. and Van Cutsem, E. (2012). Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J. Clin. Oncol. 30, 3570-3577.
59. Thompson, H. (2013). US National Cancer Institute's new Ras project targets an old foe. Nat. Med. 19, 949-950.
60. Ting, P. Y., Johnson, C. W., Fang, C., Cao, X., Graeber, T. G., Mattos, C. and Colicelli, J. (2015). Tyrosine phosphorylation of RAS by ABL allosterically enhances effector binding. FASEB J. 29, 3750-3761.
61. To, M. D., Rosario, R. D., Westcott, P. M. K., Banta, K. L. and Balmain, A. (2013). Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis. Oncogene 32, 4028-4033.
62. Tran, N. H., Cavalcante, L. L., Lubner, S. J., Mulkerin, D. L., LoConte, N. K., Clipson, L., Matkowskyj, K. A. and Deming, D. A. (2015). Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. Ther. Adv. Med. Oncol. 7, 252-262.
63. Tsai, F. D., Lopes, M. S., Zhou, M., Court, H., Ponce, O., Fiordalisi, J. J., Gierut, J. J., Cox, A. D., Haigis, K. M. and Philips, M. R. (2015). K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif. Proc. Natl. Acad. Sci. USA 112, 779-784.
64. Van Cutsem, E., Lenz, H.-J., Kohne, C.-H., Heinemann, V., Tejpar, S., Melezinek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H. et al. (2015). Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J. Clin. Oncol. 33, 692-700.
65. Vetter, I. R. (2014). The Structure of the G Domain of the Ras Superfamily. Vienna, Austria: Spinger-Verlag Wien.
66. Vigil, D., Cherfils, J., Rossman, K. L. and Der, C. J. (2010). Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat. Rev. Cancer 10, 842-857.
67. Westcott, P. M. K., Halliwill, K. D., To, M. D., Rashid, M., Rust, A. G., Keane, T. M., Delrosario, R., Jen, K.-Y., Gurley, K. E., Kemp, C. J. et al. (2015). The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature 517, 489-492.
68. Weyandt, J. D., Lampson, B. L., Tang, S., Mastrodomenico, M., Cardona, D. M. and Counter, C. M. (2015). Wild-type Hras suppresses the earliest stages of tumorigenesis in a genetically engineered mouse model of pancreatic cancer. PLoS ONE 10, e0140253.
69. Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A. et al. (2015). Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat. Commun. 6, 6744.
70. Wohlgemuth, S., Kiel, C., Krämer, A., Serrano, L., Wittinghofer, F. and Herrmann, C. (2005). Recognizing and defining true Ras binding domains I: biochemical analysis. J. Mol. Biol. 348, 741-758.
71. Xue, W., Dahlman, J. E., Tammela, T., Khan, O. F., Sood, S., Dave, A., Cai, W., Chirino, L. M., Yang, G. R., Bronson, R. et al. (2014). Small RNA combination therapy for lung cancer. Proc. Natl. Acad. Sci. USA 111, E3553-E3561.
72. Yang, M. H., Nickerson, S., Kim, E. T., Liot, C., Laurent, G., Spang, R., Philips, M. R., Shan, Y., Shaw, D. E., Bar-Sagi, D. et al. (2012). Regulation of RAS oncogenicity by acetylation. Proc. Natl. Acad. Sci. USA 109, 10843-10848.
73. Young, A., Lou, D. and McCormick, F. (2013). Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov. 3, 112-123.
74. Yuan, T. L., Fellmann, C., Lee, C.-S., Ritchie, C. D., Thapar, V., Lee, L. C., Hsu, D. J., Grace, D., Carver, J. O., Zuber, J. et al. (2014). Development of siRNA payloads to target KRAS-mutant cancer. Cancer Discov. 4, 1182-1197.
75. Zhang, Z., Wang, Y., Vikis, H. G., Johnson, L., Liu, G., Li, J., Anderson, M. W., Sills, R. C., Hong, H. L., Devereux, T. R. et al. (2001). Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat. Genet. 29, 25-33.
76. Zimmermann, G., Papke, B., Ismail, S., Vartak, N., Chandra, A., Hoffmann, M., Hahn, S. A., Triola, G., Wittinghofer, A., Bastiaens, P. I. et al. (2013). Small molecule inhibition of the KRAS-PDEdelta interaction impairs oncogenic KRAS signalling. Nature 497, 638-642.